Perspective Therapeutics (NYSE:CATX) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating
Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX – Free Report) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.90) EPS and FY2025 earnings at ($1.09) EPS. Several other equities analysts have also issued reports on the stock. Wedbush reaffirmed […]
Cantor Fitzgerald upgraded shares of Perspective Therapeutics (NYSE:CATX – Free Report) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.90) EPS and FY2025 earnings at ($1.09) EPS. Several other equities analysts have also issued reports on the stock. Wedbush reaffirmed […]
